Test predicts obesity patients’ response to Ozempic
A new study has demonstrated the clinical utility of a machine-learning gene risk score biomarker to predict patient response to Ozempic (semaglutide) and reduce variability. The study ‘Performance of a Machine-Learning Gene Risk Score Biomarker on Predicting Response to Semaglutide’ was led by the Mayo Clinic… Read More